around the neighborhood where he sometimes came
to inspect. To his knowledge, there was no similar
ailment reported from the area or by his co-workers.
Moreover, cutaneous anthrax lesion usually starts
with papule and vesicles distributed on the face or
upper extremities that rapidly breaks down to
necrotic painless ulcer with brawny edges, unlike in
our case. Antigen detection by tissue polymerase
chain reaction (PCR) is highly recommended to
perform if cutaneous anthrax is still suspected.(Titou
H et al., 2012) Suspicion of cutaneous anthrax can
also be excluded by immunohistochemistry,
although it was not available.
Finally, a favorable response toward antibacterial
monotherapy and leg compression as adjuvant
without the need to add systemic corticosteroid has
greatly supported diagnosis of bullous erysipelas.
Erysipelas in general has rapid and favorable
response to antibacterial treatment. Although many
guidelines has been established, treatment of SSTIs
including erysipelas with local complication is still
challenging because there were many variants,
degree and different etiologic agents which
associated with various pathomechanisms of
infections and clinical manifestation.(E Silvano et
al., 2016) Because SSTIs in general usually due to
Gram-positive microorganism, first line
recommended treatment are usually broad spectrum
antibiotics with more susceptibility towards Gram-
positive bacteria, such as β-lactams, cephalosporin
and clindamycin.(Edwards J et al., 2006). However,
many guidelines available do not consider target
population and its geographical differences, which is
related to epidemiology of various bacterial strains
and susceptibility toward certain antibiotics.
7
Clindamycin was chosen to treat this patient due to
its broad-spectrum activity since the infection
covered deeper structures of the skin and its
underlying structures. Clindamycin and several
antibiotics have its antitoxin property that is
beneficial to reduce early release of exotoxins from
Gram-positive microorganism, since toxin
production is associated with streptococcal and
staphylococcal infections. (Montravers P et al.,
2016).Guideline for SSTIs management from
Infectious Diseases Society of America (IDSA)
recommends the use of clindamycin for mild to
moderate erysipelas and other non-purulent
SSTIs.(Stevens DL et al., 2014). Dosage option and
adjustment should be considered based on specific
clinical condition such as renal insufficiency.
4 CONCLUSION
Bullous erysipelas is a skin and soft tissue infection
characterized by blistering and is not an uncommon
entity. However, it may still be unrecognizable if the
source and mode of infection cannot be identified.
Its clinical presentation could mimic other entities,
such as Sweet’s syndrome, pyoderma gangrenosum,
and cutaneous anthrax, each with its own
characteristics (e.g. pseudo vesiculation, brawny
edges) and underlying condition that should not be
overlooked. Histopathology may at times show
findings that are indistinguishable so that correlation
with clinical information should always be sought.
REFERENCES
Cohen PR, Honigsmann H, Kurzroc R. Acute febrile
neutrophilicdermatosis (Sweet Syndrome). Goldsmith
LA, Katz SI, Gilchrest BA, Paller A, Leffell D, Wolff
K, eds. 2008. In: Fitzpatrick’s Dermatology in General
Medicine. 8th ed. New York: McGraw Hill;. p. 362-
70.
Cowell FC, Hackett BC, Wallach D.
Pyodermagangrenosum. Goldsmith LA, Katz SI,
Gilchrest BA, Paller A, Leffell D, Wolff K, 2008. eds.
In: Fitzpatrick’s Dermatology in General Medicine.
8th ed. New York: McGraw Hill;. p.371-9.
E Silvano, Bassetti M, Bonnet E, Bouza E, Chan M,
Simone GD, et al. 2016. Hot topics in the diagnosis
and management of skin and soft-tissue infections. Int
J of Antimicrob Agents.; 48(1): 19-26.
Edwards J, Green P, Haase D. 2006. A blistering disease:
bullous erysipelas. CMAJ.; 175 (3): 247.
FY Chong, T Thirumoorthy. Blistering erysipelas: not a
rare entitiy. Singapore Med J. 2008; 49(10): 809-13.
Jendoubi F, Rohde, M, Prinz JC. 2019. Intracellular
streptococcal uptake and persistence: a potential cause
of erysipelas recurrence. Front Med., 6(6): 1-15
S Vichitra, Senanayeke S. 2016. Bacterial skin and soft
tissue infections.AistPrescr.. 39: 159-63.
Krasagakis K, Samonis G,Maniatakis P, Georgala S,
Tosca A. 2006. Bullous erysipelas: clinical
presentation, staphylococcal involvement and
methicillin resistance. Dermatology.; 212(1): 31-5.
Montravers P, Snauwaert A, Welsch C. 2016. Current
guidelines and recommendations for the management
of skin and soft tissue infections. Curr Opin Infect
Dis.; 29(2): 131-8.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP,
Goldstein EJC, Gorbach SL, et al. 2014. Practice
guidelines for the diagnosis and management of skin
and soft tissue infections: 2014 update by the
Infectious Diseases Society of America. Clin Infect
Dis.; 59(2): e10-52.